Alvotech And DKSH Partner On Adalimumab In Asia
After Deals In Canada, Europe And Israel, Alvotech Targets Asia
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
You may also be interested in...
Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules.
Hyphens Pharma has struck a licensing deal with DKSH’s Favorex to secure rights to Alvotech’s proposed ustekinumab rival to Stelara in Singapore, Malaysia and the Philippines.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.